Cures 2.0 Act
Latest action · Jan 4, 2022 Referred to the Subcommittee on Biotechnology, Horticulture, and Research.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedNov 17, 2021
- Passed HouseNot reached
- Passed SenateNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Cures 2.0 Act
This bill addresses pandemic preparedness and public health issues, caregiver and patient engagement, drug development, insurance coverage, and biomedical research.
The Department of Health and Human Services (HHS) must undertake research and other activities concerning COVID-19 and develop a strategy for future pandemics and declared emergencies. Additionally, the bill specifies actions to combat antimicrobial resistance.
HHS may award grants for caregiver training. The bill also addresses diversity in clinical trials, collecting patient experience data during clinical trials, and coverage for care related to participation in specified clinical trials.
The bill modifies the timeframe and requires additional guidance relating to expedited approval of certain breakthrough drugs, devices, or products. It also establishes two intercenter institutes within the Food and Drug Administration (FDA) focused on particular diseases that meet specified criteria.
The bill also addresses (1) coverage in Medicare, Medicaid, and the Children's Health Insurance Program for telehealth, genetic and genomic testing, and other services; (2) electronic prescribing standards for Medicare drug benefits; and (3) access to Medicare and Medicaid claims data by certain registries. Furthermore, the bill prohibits the use of geographic tracking or biometrics in Medicaid electronic visit verification systems.
The bill establishes the Advanced Research Projects Agency for Health (ARPA-H) within the National Institutes of Health to accelerate biomedical research and innovation through grants, contracts, cash prizes, and other means. The FDA may work with ARPA-H to expedite the development of medical products through specified activities.
Cosponsors 100
Members who signed on, in the order they did. Signatures ran from Nov 17, 2021 to May 20, 2022; 1 is an original cosponsor, there from the day it was introduced.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| R-MI | Fred Upton | Original | Nov 17, 2021 |
| D-IN | André Carson | Nov 18, 2021 | |
| D-NH | Ann M. Kuster | Nov 18, 2021 | |
| D-MD | Anthony G. Brown | Nov 18, 2021 | |
| D-MS | Bennie G. Thompson | Nov 18, 2021 | |
| R-PA | Brian K. Fitzpatrick | Nov 18, 2021 | |
| D-MI | Daniel T. Kildee | Nov 18, 2021 | |
| R-WV | David B. McKinley | Nov 18, 2021 | |
| D-NC | David E. Price | Nov 18, 2021 | |
| D-RI | David N. Cicilline | Nov 18, 2021 | |
| D-MI | Debbie Dingell | Nov 18, 2021 | |
| D-WA | Derek Kilmer | Nov 18, 2021 | |
| R-AK | Don Young | Nov 18, 2021 | |
| D-NJ | Donald M. Payne, Jr. | Nov 18, 2021 | |
| D-VA | Donald S. Beyer, Jr. | Nov 18, 2021 |
Committees 11
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| House | Energy and Commerce Committee | Referred Nov 17, 2021 |
| Health Subcommittee | Referred Nov 18, 2021 | |
| House | Ways and Means Committee | Referred Nov 17, 2021 |
| Health Subcommittee | Referred Nov 17, 2021 | |
| House | Budget Committee | Referred Nov 17, 2021 |
| House | Science, Space, and Technology Committee | Referred Nov 17, 2021 |
| House | Agriculture Committee | Referred Nov 17, 2021 |
| Conservation, Research, and Biotechnology Subcommittee | Referred Jan 4, 2022 | |
| House | Education and Workforce Committee | Referred Nov 17, 2021 |
| House | Armed Services Committee | Referred Nov 17, 2021 |
| House | Natural Resources Committee | Referred Nov 17, 2021 |
| Indian and Insular Affairs Subcommittee | Referred Dec 2, 2021 | |
| House | Veterans' Affairs Committee | Referred Nov 17, 2021 |
| Health Subcommittee | Referred Dec 7, 2021 | |
| House | Homeland Security Committee | Referred Nov 17, 2021 |
| Oversight, Investigations, and Accountability Subcommittee | Referred Nov 18, 2021 | |
| House | Judiciary Committee | Referred Nov 17, 2021 |
Actions 8
Everything that happened, newest first.
- Jan 4, 2022Referred to the Subcommittee on Biotechnology, Horticulture, and Research.
- Dec 7, 2021Referred to the Subcommittee on Health.
- Dec 2, 2021Referred to the Subcommittee for Indigenous Peoples of the United States.
- Nov 18, 2021Referred to the Subcommittee on Health.
- Nov 18, 2021Referred to the Subcommittee on Oversight, Management, and Accountability.
- Nov 17, 2021Introduced in House
- Nov 17, 2021Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, the Budget, Science, Space, and Technology, Agriculture, Education and Labor, Armed Services, Natural Resources, Veterans' Affairs, Homeland Security, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Nov 17, 2021Referred to the Subcommittee on Health.
Research
What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.
Constitutional authority
The sponsor’s statement, as printed in the Congressional Record, vol. 167, no. 200, November 17, 2021, page H6370.
Printed hearings 4
Hearings whose printed record names this bill, newest first: hearings on it, and wider hearings where it came up.
| Number | Hearing | Committee | Held |
|---|---|---|---|
| Serial No. 117-75 | THE FUTURE OF MEDICINE: LEGISLATION TO ENCOURAGE INNOVATION AND IMPROVE OVERSIGHT308 pages | Energy and Commerce Committee | Mar 17, 2022 |
| S. Hrg. 117-809 | PRESCRIPTION DRUG PRICE INFLATION: AN URGENT NEED TO LOWER DRUG PRICES IN MEDICARE224 pages | Finance Committee | Mar 16, 2022 |
| Serial No. 117-65 | HEARING ON; FDA USER FEE REAUTHORIZATION: ENSURING SAFE AND EFFECTIVE DRUGS AND BIOLOGICS229 pages | Energy and Commerce Committee | Feb 3, 2022 |
| Serial No. 117-60 | THE FUTURE OF BIOMEDICINE: TRANSLATING BIOMEDICAL RESEARCH INTO PERSONALIZED HEALTH CARE209 pages | Energy and Commerce Committee | Dec 8, 2021 |
CRS reports 2
Congressional Research Service work that CRS links to this bill or the law it became, newest first.
Cite it 2
Products on other subjects that cite it, usually among other measures.
| Product | Title | Kind | Published |
|---|---|---|---|
| R47074 | Advanced Research Projects Agency for Health (ARPA-H): Congressional Action and Selected Policy Issues Archived | Report | Aug 12, 2022 |
| R47024 | Immunization Information Systems: Overview and Current Issues | Report | Feb 1, 2022 |
Related bills 7
Companion bills and other measures the record links to this one.
| Bill | Title | Relationship | Latest action |
|---|---|---|---|
| S 368 | Telehealth Modernization Act | Related bill | Feb 23, 2021 |
| HR 1397 | TIKES Act | Related bill | Feb 27, 2021 |
| S 1798 | TIKES Act | Related bill | May 25, 2021 |
| S 2076 | PASTEUR Act of 2021 | Related bill | Jun 16, 2021 |
| HR 3932 | PASTEUR Act of 2021 | Related bill | Aug 2, 2021 |
Titles 2
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- To continue the acceleration of the discovery, development, and delivery of 21st century cures, and for other purposes.
- Short Title(s) as Introduced
- Cures 2.0 Act
Subjects
Assigned by the Library of Congress. Policy area: Health.
- Administrative law and regulatory procedures
- Administrative remedies
- Advisory bodies
- Appropriations
- Cardiovascular and respiratory health
- Cell biology and embryology
- Centers for Disease Control and Prevention (CDC)
- Child care and development
- Child health
- Computers and information technology
- Congressional oversight
- Department of Health and Human Services
- Digestive and metabolic diseases
- Digital media
- Drug safety, medical device, and laboratory regulation
- Drug therapy
- Economic performance and conditions
- Education programs funding
- Emergency medical services and trauma care
- Executive agency funding and structure
- Federal officials
- Food and Drug Administration (FDA)
- Genetics
- Government information and archives
- Government studies and investigations
- Health
- Health care costs and insurance
- Health care coverage and access
- Health care quality
- Health facilities and institutions
- Health information and medical records
- Health personnel
- Health programs administration and funding
- Health promotion and preventive care
- Health technology, devices, supplies
- Hereditary and development disorders
- Higher education
- Home and outpatient care
- Hospital care
- Immunology and vaccination
- Indian social and development programs
- Infectious and parasitic diseases
- Intergovernmental relations
- Internet and video services
- Internet, web applications, social media
- Licensing and registrations
- Long-term, rehabilitative, and terminal care
- Manufacturing
- Medicaid
- Medical education
- Medical research
- Medical tests and diagnostic methods
- Medicare
- Military medicine
- Minority health
- National Institutes of Health (NIH)
- Poverty and welfare assistance
- Preschool education
- Prescription drugs
- Public contracts and procurement
- Research administration and funding
- Right of privacy
- State and local government operations
- Student aid and college costs
- User charges and fees
- Veterans' medical care
- World health
Text 1
Each version as it was printed, newest first.
- Nov 17, 2021Introduced in House
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.
